MINI FUTURE OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 15:48:29 2024-05-17 EDT | ||
| 10.21 EUR | -4.13% |
|
| Current month | -32.61% | ||
| 1 month | -32.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 10.21 | -4.13% |
| 24-05-16 | 10.65 | -3.01% |
| 24-05-15 | 10.98 | -7.19% |
| 24-05-14 | 11.83 | +1.20% |
| 24-05-13 | 11.69 | -5.50% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 03:48 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK7CWU |
| ISIN | DE000JK7CWU9 |
| Date issued | 2024-04-12 |
| Strike | 555.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.45 € |
|---|---|
| Lowest since issue | 10.21 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
